See more : JDM JingDaMachine(Ningbo)Co.Ltd (603088.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Integra LifeSciences Holdings Corporation (IART) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Integra LifeSciences Holdings Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- PT Bank Central Asia Tbk (BBCA.JK) Income Statement Analysis – Financial Results
- Prinx Chengshan Holdings Limited (1809.HK) Income Statement Analysis – Financial Results
- Talon International, Inc. (TALN) Income Statement Analysis – Financial Results
- Gansu Jiu Steel Group Hongxing Iron & Steel Co.,Ltd. (600307.SS) Income Statement Analysis – Financial Results
- Westhaven Gold Corp. (WTHVF) Income Statement Analysis – Financial Results
Integra LifeSciences Holdings Corporation (IART)
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.37B | 1.52B | 1.47B | 1.19B | 992.08M | 882.73M | 928.31M | 836.21M | 830.87M | 780.08M | 732.07M | 682.49M | 654.60M | 550.46M | 419.30M | 277.94M | 229.83M | 185.60M | 112.63M | 93.44M | 64.99M | 42.50M | 17.50M | 14.70M | 13.10M | 10.20M |
| Cost of Revenue | 653.18M | 587.36M | 597.81M | 520.83M | 564.68M | 571.50M | 435.51M | 349.09M | 326.54M | 352.80M | 334.09M | 314.43M | 299.15M | 268.19M | 244.92M | 252.83M | 214.67M | 168.31M | 105.54M | 87.30M | 70.60M | 45.77M | 36.01M | 26.82M | 21.80M | 6.10M | 5.20M | 4.70M | 3.50M |
| Gross Profit | 888.39M | 970.31M | 944.64M | 851.03M | 952.88M | 900.95M | 752.73M | 642.99M | 556.19M | 575.50M | 502.13M | 516.44M | 480.93M | 463.88M | 437.57M | 401.78M | 335.79M | 250.98M | 172.40M | 142.53M | 115.00M | 66.85M | 57.43M | 38.17M | 20.70M | 11.40M | 9.50M | 8.40M | 6.70M |
| Gross Profit Ratio | 57.63% | 62.29% | 61.24% | 62.03% | 62.79% | 61.19% | 63.35% | 64.81% | 63.01% | 62.00% | 60.05% | 62.16% | 61.65% | 63.37% | 64.11% | 61.38% | 61.00% | 59.86% | 62.03% | 62.02% | 61.96% | 59.36% | 61.46% | 58.74% | 48.71% | 65.14% | 64.63% | 64.12% | 65.69% |
| Research & Development | 174.59M | 101.19M | 93.05M | 77.38M | 79.57M | 78.04M | 63.46M | 58.16M | 50.90M | 51.60M | 52.09M | 51.01M | 51.45M | 48.11M | 44.28M | 60.50M | 30.66M | 25.73M | 11.96M | 14.12M | 12.81M | 8.30M | 7.99M | 7.52M | 8.70M | 8.40M | 6.40M | 6.30M | 5.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 592.64M | 616.32M | 637.45M | 594.53M | 687.60M | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 6.10M |
| Other Expenses | 69.16M | 13.88M | 16.91M | 27.76M | 27.03M | 8.29M | 1.35M | 845.00K | 4.59M | -763.00K | -1.80M | -721.00K | 16.43M | 12.02M | 14.36M | 12.88M | 12.65M | 8.80M | 6.06M | 4.27M | 3.08M | -3.55M | 2.78M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| Operating Expenses | 836.39M | 731.39M | 747.41M | 699.66M | 794.20M | 789.95M | 707.92M | 527.65M | 476.61M | 509.96M | 459.04M | 442.66M | 426.02M | 365.19M | 339.75M | 354.37M | 268.50M | 192.24M | 116.29M | 117.75M | 75.36M | 45.34M | 43.14M | 56.55M | 33.10M | 25.50M | 28.50M | 17.90M | 12.70M |
| Cost & Expenses | 1.43B | 1.32B | 1.35B | 1.22B | 1.36B | 1.36B | 1.14B | 876.74M | 803.15M | 862.76M | 793.12M | 757.09M | 725.17M | 633.37M | 584.66M | 607.19M | 483.17M | 360.55M | 221.83M | 205.05M | 145.95M | 91.11M | 79.16M | 83.37M | 54.90M | 31.60M | 33.70M | 22.60M | 16.20M |
| Interest Income | 17.20M | 11.92M | 6.74M | 9.30M | 10.78M | 2.80M | 255.00K | 24.00K | 13.00K | 168.00K | 443.00K | 1.21M | 465.00K | 225.00K | 631.00K | 2.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 51.38M | 49.59M | 50.40M | 71.58M | 53.96M | 64.68M | 35.02M | 25.80M | 23.52M | 21.97M | 19.79M | 22.24M | 27.64M | 18.36M | 23.23M | 30.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.51M | 121.12M | 123.67M | 118.99M | 114.70M | 115.70M | 88.90M | 72.67M | 9.95M | 12.40M | 47.01M | 18.54M | 16.43M | 39.17M | 39.69M | 33.15M | 27.04M | 21.48M | 13.22M | 11.59M | 9.04M | 7.16M | 6.26M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| EBITDA | 274.01M | 391.10M | 366.33M | 267.93M | 231.03M | 241.04M | 135.23M | 231.73M | 195.59M | 172.24M | 40.07M | 116.46M | 106.31M | 139.64M | 136.07M | 79.34M | 67.29M | 58.74M | 69.33M | 36.37M | 48.69M | 25.81M | 20.54M | -13.21M | -12.40M | -16.60M | -17.20M | -7.50M | -4.60M |
| EBITDA Ratio | 17.77% | 17.77% | 15.57% | 14.06% | 13.57% | 9.73% | 5.62% | 13.11% | 10.66% | 8.33% | 10.61% | 11.17% | 9.21% | 18.86% | 20.24% | 12.44% | 16.60% | 19.61% | 25.21% | 14.08% | 14.39% | 22.91% | 15.97% | -32.65% | -34.12% | -83.43% | -130.61% | -71.76% | 144.12% |
| Operating Income | 111.53M | 238.92M | 197.23M | 151.37M | 178.98M | 111.00M | 44.80M | 115.34M | 79.59M | 65.54M | -3.64M | 73.78M | 54.91M | 98.69M | 97.82M | 47.41M | 67.29M | 58.74M | 56.11M | 24.78M | 39.65M | 19.19M | 14.29M | -18.38M | -12.40M | -14.10M | -19.00M | -9.50M | -6.00M |
| Operating Income Ratio | 7.23% | 15.34% | 12.79% | 11.03% | 11.79% | 7.54% | 3.77% | 11.63% | 9.02% | 7.06% | -0.44% | 8.88% | 7.04% | 13.48% | 14.33% | 7.24% | 12.22% | 14.01% | 20.19% | 10.78% | 21.36% | 17.04% | 15.29% | -28.29% | -29.18% | -80.57% | -129.25% | -72.52% | -58.82% |
| Total Other Income/Expenses | -30.46M | -25.03M | 17.45M | -57.85M | -33.66M | -53.60M | -33.42M | -24.93M | -18.92M | -24.88M | -21.15M | -21.75M | -26.42M | -16.58M | -24.67M | -16.41M | -7.23M | -10.44M | -1.00M | 3.23M | 3.54M | 3.54M | 1.26M | 7.54M | 7.43M | 5.26M | 2.00M | 1.90M | -19.30M |
| Income Before Tax | 81.07M | 213.89M | 214.68M | 93.52M | 60.10M | 57.40M | 11.39M | 90.41M | 60.67M | 42.98M | -24.79M | 52.03M | 28.49M | 82.11M | 73.15M | 31.01M | 60.06M | 48.31M | 55.10M | 28.01M | 43.19M | 22.73M | 15.54M | -10.85M | -7.80M | -12.30M | -17.00M | -7.60M | -25.30M |
| Income Before Tax Ratio | 5.26% | 13.73% | 13.92% | 6.82% | 3.96% | 3.90% | 0.96% | 9.11% | 6.87% | 4.63% | -2.96% | 6.26% | 3.65% | 11.22% | 10.72% | 4.74% | 10.91% | 11.52% | 19.83% | 12.19% | 23.27% | 20.18% | 16.63% | -16.69% | -18.35% | -70.29% | -115.65% | -58.02% | -248.04% |
| Income Tax Expense | 13.33M | 33.34M | 45.60M | -40.37M | 9.90M | -3.40M | -53.36M | 15.84M | 53.82M | 8.98M | -7.81M | 10.83M | 505.00K | 16.45M | 22.20M | -3.93M | 26.59M | 18.90M | 17.91M | 10.81M | 16.33M | -12.55M | -10.86M | 108.00K | -1.80M | -1.80M | -2.00M | -2.00M | 19.40M |
| Net Income | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M | 60.80M | 64.74M | 74.56M | -3.52M | 34.00M | -16.98M | 41.20M | 27.99M | 65.67M | 50.96M | 34.93M | 33.47M | 29.41M | 37.19M | 17.20M | 26.86M | 35.28M | 26.16M | -11.43M | -6.00M | -12.30M | -17.00M | -7.50M | -25.40M |
| Net Income Ratio | 4.39% | 11.59% | 10.96% | 9.76% | 3.31% | 4.13% | 5.45% | 7.52% | -0.40% | 3.66% | -2.03% | 4.96% | 3.59% | 8.97% | 7.47% | 5.34% | 6.08% | 7.01% | 13.38% | 7.48% | 14.47% | 31.32% | 28.00% | -17.58% | -14.12% | -70.29% | -115.65% | -57.25% | -249.02% |
| EPS | 0.87 | 2.18 | 2.00 | 1.58 | 0.59 | 0.73 | 0.83 | 1.00 | -0.05 | 0.52 | -0.30 | 0.74 | 0.52 | 1.11 | 0.88 | 0.49 | 0.61 | 0.50 | 0.62 | 0.28 | 0.46 | 0.61 | 0.54 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| EPS Diluted | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | 0.72 | 0.82 | 0.94 | -0.05 | 0.52 | -0.29 | 0.72 | 0.48 | 1.09 | 0.87 | 0.48 | 0.56 | 0.49 | 0.57 | 0.28 | 0.43 | 0.57 | 0.47 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| Weighted Avg Shares Out | 78.17M | 83.00M | 84.70M | 84.65M | 85.64M | 82.86M | 78.39M | 74.72M | 73.88M | 65.48M | 56.83M | 55.90M | 53.66M | 59.10M | 58.08M | 55.56M | 55.42M | 58.60M | 60.39M | 60.13M | 58.14M | 58.04M | 46.71M | 35.11M | 33.60M | 32.28M | 29.57M | 28.11M | 20.99M |
| Weighted Avg Shares Out (Dil) | 80.34M | 83.52M | 85.49M | 85.23M | 86.49M | 84.45M | 79.12M | 79.19M | 73.88M | 65.92M | 57.60M | 57.03M | 58.99M | 60.30M | 58.58M | 56.76M | 59.16M | 65.49M | 69.13M | 62.20M | 66.21M | 61.79M | 55.59M | 35.11M | 34.12M | 32.28M | 29.57M | 28.11M | 20.99M |
Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut
The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Integra LifeSciences Holdings Corporation(IART) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...
IART INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Integra LifeSciences Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK , Oct. 25, 2023 /PRNewswire/ -- Attorney Advertising, Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corporation ("Integra" or "the Company") (NASDAQ:...
Integra LifeSciences Holdings Corporation (IART) Q3 2023 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2023 Earnings Call October 25, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director of Investor Relations Jan De Witte - President and Chief Executive Officer Lea Daniels Knight - Chief...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
NEW YORK , Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Robert S.
Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
Integra LifeSciences (IART) Q3 Earnings and Revenues Miss Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.86 per share a year ago.
Integra LifeSciences Reports Third Quarter 2023 Financial Results
PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023.
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Integra LifeSciences Holdings Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - IART
NEW YORK , Oct. 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQ: IART) between March 11, 2019 and May 22, 2023, both dates...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Integra LifeSciences Holdings Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 13, 2023 - (NASDAQ: IART)
NEW YORK , Oct. 24, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Integra LifeSciences Holdings Corporation. Shareholders who purchased shares of IART during the class period listed are encouraged to contact the firm...
Source: https://incomestatements.info
Category: Stock Reports